Testosterone Therapy Threatens Fertility — Here's How to Protect Sperm
TRT suppresses sperm production in reproductive-age men, but new formulations and adjunct therapies may preserve fertility options.
Summary
Testosterone replacement therapy (TRT) is increasingly prescribed for men with low testosterone, but exogenous androgens sharply suppress the hormonal signals needed for sperm production. This review from Cleveland Clinic experts explains how TRT disrupts the hypothalamic-pituitary-gonadal axis, drastically lowering intratesticular testosterone and impairing spermatogenesis. While sperm production often resumes after stopping TRT, recovery is slow and unpredictable — a serious concern for men planning families. Adjunct treatments like aromatase inhibitors, selective estrogen receptor antagonists, and gonadotropins (hCG, FSH) can help preserve or restore fertility. Newer short-acting TRT formulations, such as oral testosterone undecanoate and nasal testosterone gel, may cause less suppression and partially preserve sperm production.
Detailed Summary
Testosterone replacement therapy is one of the most commonly prescribed hormonal interventions for men, particularly as symptomatic testosterone deficiency becomes more prevalent with age. Yet for reproductive-age men, TRT carries a critical and often underappreciated risk: profound suppression of sperm production that can persist long after treatment ends.
This comprehensive 2025 review published in Nature Reviews Urology examines the mechanisms by which exogenous testosterone disrupts spermatogenesis. When testosterone is administered externally, it suppresses gonadotropin-releasing hormone and downstream signals, sharply reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The result is a steep drop in intratesticular testosterone — the locally high levels essential for sperm maturation — effectively halting or severely impairing spermatogenesis.
A key concern identified by the authors is the variability in sperm recovery after TRT cessation. While most men eventually see some restoration of sperm production, the timeline is highly unpredictable and can extend for months to years, complicating family planning decisions. This uncertainty demands proactive fertility counseling before TRT initiation in any man of reproductive age.
The review highlights several pharmacological strategies to mitigate fertility risk. Aromatase inhibitors and selective estrogen receptor antagonists can boost endogenous gonadotropin levels, while exogenous gonadotropins — human chorionic gonadotropin (hCG) and FSH — can directly stimulate testicular function during or after TRT. These approaches can help preserve or restore spermatogenesis in select patients.
Importantly, the authors note that newer, shorter-acting TRT formulations — oral testosterone undecanoate and nasal testosterone gel — may incompletely suppress the HPG axis and partially preserve sperm production, offering potential options for symptomatic men who still wish to maintain fertility. Nonetheless, TRT remains contraindicated in men actively trying to conceive.
Key Findings
- TRT drastically reduces intratesticular testosterone, suppressing spermatogenesis in reproductive-age men.
- Sperm recovery after TRT cessation is highly variable, potentially taking months to years.
- hCG, FSH, aromatase inhibitors, and SERMs can preserve or restore sperm production during TRT.
- Short-acting formulations like nasal testosterone gel may partially preserve the HPG axis and fertility.
- TRT is contraindicated in men actively trying to conceive; counseling before initiation is essential.
Methodology
This is a narrative review article published in Nature Reviews Urology, synthesizing existing literature on TRT and its effects on male fertility. The authors are urologists from the Cleveland Clinic's Glickman Urological Institute. No primary data or clinical trial was conducted as part of this publication.
Study Limitations
As a review article based solely on an abstract, the full scope of included studies, quality assessment, and specific evidence grading cannot be evaluated. The review may reflect publication bias in underlying studies, and individual patient variability in HPG axis suppression and recovery limits generalizability of clinical recommendations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.